Search by Abstract Number Results

Abstract Number: 0955 • ACR Convergence 2025
Surveying RNA methylation in scleroderma highlights roles for demethylases ALKBH5 and FTO in fibrosis
Alexander Cai¹, Alyssa Rosek¹, Neha Khanna¹, Anna Webber¹, Karly Kozicki¹, Dinesh Khanna² and Pei-Suen Tsou², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Recent studies indicate that genes involved in RNA methylation may play a significant role in cellular functions, and disruptions in RNA methylation have been…
Abstract Number: 0955 • ACR Convergence 2024
Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis
Goncalo Boleto¹, Anne Cauvet², James Rose³, Lih-Yun Hsu³, Richard A. Miller³ and Yannick Allanore⁴, ¹Rheumatology Department, Unidade Local de Saúde Santa Maria, Centro Académico de Medicina de Lisboa, Lisboa, Portugal., Lisbon, Portugal, ²Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ³Corvus Pharmaceuticals, 863 Mitten Road, Burlingame, Burlingame, CA, ⁴Université Paris Cité, Paris, France
Background/Purpose: T cells abnormal activation plays a pivotal role in the early inflammatory stages of systemic sclerosis (SSc). Compelling evidence supports that SSc has a…
Abstract Number: 0955 • ACR Convergence 2023
GRB2 Serves as a Viable Target Against Skin Fibrosis in Systemic Sclerosis by Regulating Endothelial Cell Apoptosis
Yan Huang, Han Zhao, Xiangguang Shi, Jing Liu, Jui-Ming Lin, Qianqian Ma, Shuai Jiang, Weilin Pu, Yanyun Ma, Jianlan Liu, Wenyu Wu, Jiucun Wang and Qingmei Liu, Shanghai, Shanghai, China
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by vascular and immune system dysfunction, along with tissue fibrosis. Vascular damage has been recognized as…
Abstract Number: 0955 • ACR Convergence 2022
Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort
SABRINA HAMROUN¹, Marion Couderc², Rene-Marc Flipo³, Laure Gossec⁴, Christophe Richez⁵, Rakiba Belkhir⁶, Aline Frazier-Mironer⁷, Valerie Devauchelle⁸, Hubert Marotte⁹, Jérémie SELLAM¹⁰, elisabeth gervais¹¹, Alban DEROUX¹², Cédric Lukas¹³, Emmanuelle Dernis¹⁴, Emmanuel Chatelus¹⁵ and Anna Molto¹⁶, ¹Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, ²University Hospital, Clermont-Ferrand, France, ³CHU Lille, Boulogne-Billancourt, France, ⁴Sorbonne Université, Paris, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁷APHP Hôpital Lariboisire, Paris, France, ⁸Université de Bretagne Occidentale, Brest, France, ⁹INSERM 1059, Saint-Etienne, France, ¹⁰Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ¹¹chu poitiers, Poitiers, France, ¹²CHU Grenoble, Grenoble, France, ¹³University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ¹⁴LE MANS general hospital, LE MANS, France, ¹⁵University Hospital of Strasbourg, Strasbourg, France, ¹⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge…
Abstract Number: 0955 • ACR Convergence 2021
The Effect of Treatment with the Complement C5a Receptor Inhibitor Avacopan on Health-Related Quality of Life in ANCA-Associated Vasculitis
Vibeke Strand¹, Pirow Bekker², Huibin Yue², David R.W. Jayne³ and Peter Merkel⁴, ¹Stanford University School of Medicine, Portola Valley, CA, ²ChemoCentryx, San Carlos, CA, ³University of Cambridge, Cambridge, United Kingdom, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Avacopan, an oral C5a receptor inhibitor, was evaluated in ANCA-associated vasculitis (AAV). Efficacy and safety results were reported previously. Health-related quality of life (HRQoL)…
Abstract Number: 0955 • ACR Convergence 2020
Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)
Rohit Aggarwal¹, Christina Charles-Schoeman², Joachim Schessl³, Zsuzsanna Bata-Csorgo⁴, Mazen Dimachkie⁵, Zoltan Griger⁶, Sergey Moiseev⁷, Chester Oddis⁸, Elena Schiopu⁹, Jiří Vencovský¹⁰, Beckmann Irene¹¹, Clodi Elisabeth¹¹, Todd Levine¹² and and the ProDERM Investigators¹³, ¹University of Pittsburgh, Pittsburgh, PA, ²University of California, Los Angeles, Los Angeles, CA, ³Städtisches Klinikum Karlsruhe, Karlsruhe, Germany, ⁴University of Szeged, Faculty of Medicine, Szeged, Hungary, ⁵Univeristy of Kansas, Medical Center, Kansas City, KS, ⁶University of Debrecen, Debrecen, Hungary, ⁷First Moscow State Medical University, Moscow, Russia, ⁸Department of Medicine, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Michigan Medicine, Ann Arbor, MI, ¹⁰Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹¹Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria, ¹²Phoenix Neurological Associates, LTD, Phoenix, AZ, ¹³Different Institutions in several countries, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rash and progressive proximal muscle weakness. Intravenous immunoglobulin (IVIg) has long been…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].